-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191

Benzinga·11/13/2026 17:50:35
Listen to the news
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $185 to $191.